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Abstract
Background: Recent evidence suggests a crucial role of the endocannabinoid system, including the cannabinoid 1 receptor
(CNR1), in intestinal inflammation. We therefore investigated the influence of the CNR1 1359 G/A (p.Thr453Thr; rs1049353)
single nucleotide polymorphism (SNP) on disease susceptibility and phenotype in patients with ulcerative colitis (UC) and
Crohn’s disease (CD).
Methods: Genomic DNA from 579 phenotypically well-characterized individuals was analyzed for the CNR1 1359 G/A SNP.
Amongst these were 166 patients with UC, 216 patients with CD, and 197 healthy controls.
Results: Compared to healthy controls, subjects A/A homozygous for the CNR1 1359 G/A SNP had a reduced risk to develop
UC (p=0.01, OR 0.30, 95% CI 0.12–0.78). The polymorphism did not modulate CD susceptibility, but carriers of the minor A
allele had a lower body mass index than G/G wildtype carriers (p=0.0005). In addition, homozygous carriers of the G allele
were more likely to develop CD before 40 years of age (p=5.9610
27) than carriers of the A allele.
Conclusion: The CNR1 p.Thr453Thr polymorphism appears to modulate UC susceptibility and the CD phenotype. The
endocannabinoid system may influence the manifestation of inflammatory bowel diseases, suggesting endocannabinoids
as potential target for future therapies.
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Introduction
Anecdotal reports suggest that marijuana- or tetrahydrocannab-
inol-containing products may be effective in alleviating symptoms in
patients with ulcerative colitis (UC) and Crohn’s disease (CD). [1,2]
This is supported by recent studies of our group and others suggesting
that pharmacological activation of the cannabinoid 1 (CB1) receptor
with selective receptor agonists decreases the inflammatory response
in various murine models of colonic inflammation including
dinitrobenzene sulphonic acid (DNBS)-, trinitrobenzene sulphonic
acid (TNBS)- and dextran sodium sulfate (DSS)-induced colitis. [3–7]
Interestingly, pharmacological blockade of CB1 receptors or genetic
ablation of CB1 receptors (CNR1
2/2 mice) aggravates intestinal
inflammation in these models, [3,7] emphasizing the physiological
relevance of the CB1 receptor in the protection against intestinal
inflammation. Increased mucosal levels of the endocannabinoid
anandamide during intestinal inflammation in humans further stress
the role of the CB1 receptor and the endocannabinoid system in
intestinal inflammation. [4] Thus, present knowledge suggests up-
regulation of endocannabinoids as an important protective mecha-
nism in intestinal inflammation.
The endocannabinoid system and the CB1 and CB2 receptors
seem to be crucially involved in the regulation of multiple
physiological functions, e.g. in the heart, where they relax coronary
arteries and decrease cardiac work, [8] in organ perfusion, [9] in
metabolic homeostasis, [10,11] and in the regulation of bone mass
by osteoclasts, [12] as well as in the protection against stress
responses,inflammation,andassociatedrepairmechanisms.[13,14]
Although recent evidence suggests that the endocannabinoid system
is involved in many physiological and pathophysiological functions
of the gastrointestinal tract such as intestinal motility, secretion, and
intestinal inflammation [3,15–20], the exact mechanisms underly-
ing these findings are not yet known. It was recently suggested that
CB1 signaling may be up-regulated during colitis, [3] but it is
unknown whether this is a specific feature of the colitis model or a
general response to intestinal inflammation.
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9453Moreover, the role of the CB1 receptor in human inflammatory
bowel disease (IBD) has not been clarified. Increased anandamide
levels were found in mucosal biopsies from UC patients, suggesting
a role of the endocannabinoid system in UC. [4] In contrast, the
colonic expression of the endocannabinoid 2-acyl-glycerol (2-AG)
is not increased in UC. [4] So far, however, no other studies
analyzing the endocannabinoid system or the pharmacological
effects of cannabinoids in human IBD have been published.
Gastrointestinal inflammation is likely the result of multiple factors,
e.g., increased pro-inflammatory stimuli and reduced protective
capability. The overall balance between pro- and anti-inflammatory
mechanisms may determine the progression and severity of intestinal
inflammation. [21,22] Given the results of recent genome-wide
association studies, [23] genetic susceptibility is an important factor
contributing to IBD development. Moreover, knowledge of genetic
susceptibility factors could provide important pathophysiologic
insights for the generation of novel IBD therapeutics.
Considering our previous work on the endocannabinoid system
in murine intestinal inflammation, [3,6,7,24] we hypothesized that
genetic variants in the CNR1 gene, which may modulate CB1
receptor function, could be associated with an increased
susceptibility to IBD. To test our hypothesis, we genotyped a
cohort of more than 550 individuals including 382 IBD patients
and analyzed whether the 1359 G/A (p.Thr453Thr; rs1049353)
single nucleotide polymorphism (SNP) within the CNR1 gene
encoding the CB1 receptor modulates the susceptibility to CD and
UC or results in a certain IBD phenotype. The selection of the
CNR1 1359 G/A SNP was based on previous studies reporting
that this polymorphism is associated with other disorders
modulated by the endocannabinoid system such as alcohol
dependence and hebephrenic schizophrenia. [25,26]
Methods
Ethics Statement
The study was approved by the Ethics Committee of the
Medical Faculty of the University of Munich. All participating
subjects gave their written, informed consent prior to the genetic
analysis.
Human Study Population
The study population comprised 579 individuals, including 216
patients with CD, 166 with UC, and 197 healthy, unrelated
controls. Patients and controls were recruited at the IBD center of
the Ludwig-Maximilians-University Munich, Campus Grossha-
dern, from September 2002 to December 2006. The diagnoses of
CD and UC were established following clinical guidelines, using
endoscopic, radiological, and histopathologic criteria. Table 1
shows the baseline characteristics of the study population. All 197
controls were unrelated, healthy individuals of Caucasian origin
and sex-matched (by frequency) to the CD group. Controls were
healthy blood donors without a history or family history of IBD.
Demographics and routine clinical data (including location and
behavior of IBD, disease-related complications, and prescription
data of immunosuppressive and immunomodulatory therapy e.g.,
azathioprine, 6-mercaptopurine, methotrexate, infliximab) were
recorded by retrospective analysis of the clinical charts by two
independent investigators and an interview including a question-
naire at the time of enrollment. All data were collected blind to the
CNR1 genotype. Patients with CD or UC were grouped according
to age at diagnosis, disease localization, and behavior status of the
Vienna classification, [27] and the recent modifications suggested
by the Montreal classification. [28]
DNA Extraction and Genotyping of the CNR1
Polymorphism
Recently, a guanosine-to-adenine substitution at nucleotide
position 1359 has been identified in the CNR1 gene (rs1049353)
[25,29]. Thus, three genotypes (GG, GA, AA) are possible.
Genomic DNA was isolated from peripheral blood leukocytes by
standard procedures using the DNA blood mini kit from Qiagen
(Hilden, Germany). Genotyping was done as previously described
[7,30]. Briefly, a single 20-ml PCR was performed to genotype this
Table 1. Demographic characteristics of the study population.
(1)
CD (n=216)
(2)
UC (n=166)
(3)
Controls (n=197)
(1) vs (2)
p value
(1) vs (3)
p value
(2) vs (3)
p value
Gender
Male (%) 105 (48.6%) 83 (50.0%) 114 (58.0%) p=0.84 p=0.06 p=0.14
Female (%) 111 (51.4%) 83 (50.0%) 83 (42.0%)
Age (yr)
Mean 6 SD 41.4611.8 43.3614.4 43.9621.6 p=0.17 p=0.19 p=0.75
Range 17–71 19–85 0–80
Body mass index
Mean 6 SD 23.163.9 24.264.2 p=0.02
Range 16–34 16–41
Age at diagnosis (yr)
Mean 6 SD 28.1611.4 31.8613.7 p=0.006
Range 7–67 9–81
Disease duration (yr)
Mean 6 SD 13.568.5 11.567.6 p=0.016
Range 2–44 1–40
Positive family history of IBD (%) 30 (13.9%) 21 (12.7%) p=0.76
doi:10.1371/journal.pone.0009453.t001
CNR1 in IBD
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each of the following primers 59-GAAAGCTGCATCAA-
GAGCCC-39 (forward) and 59-TTTTCCTGTGCTGCCA-
GGG-39 (reverse). Other conditions were as follows: 1.5 mM
MgCl2, 400 mM of each dNTP, 1.25 U Taq polymerase, and 16
reaction buffer (Life Technologies, Rockville, MD). DNA
amplification was performed with 40 cycles of 94uC, 60uC, and
72uC for 30 seconds each, preceded by a single cycle of 95uC for
15 minutes and followed by a single cycle of 72uC for 5 minutes.
Five ml of the resulting 111 bp PCR product were then digested
overnight with 10 U of Mspl (New England Biolabs, Beverly, MA)
at 37uC. This resulted in fragments of 92 and 19 bp, when a G was
present at nucleotide position 385, while the fragment remained
uncut, when an A was present. Restriction digests were analyzed
by electrophoresis of the digestion mixture in a 2% agarose gel
stained with ethidium bromide. The assay was verified by
sequencing the PCR product and the digested PCR fragments of
all possible genotypes.
Statistics
Fisher’s exact test was used for comparison between cate-
gorical variables. All tests were two-tailed. P values ,0.05 were
considered as significant. Analyses were performed using SPSS
14.0.1 software for Windows.
Results
The CNR1 1359 G/A (p.Thr453Thr) Polymorphism
Modulates UC but Not CD Susceptibility
Given the above reported increased CB1 receptor expression in
several models of intestinal inflammation and previous studies
implicating the CNR1 1359 G/A (p.Thr453Thr) SNP in
endocannabinoid-mediated diseases, [25,31] we investigated
whether this polymorphism modulates susceptibility and pheno-
type of CD and UC. The demographic characteristics of the IBD
and control population analyzed are given in Table 1. The CD
patients were classified with regard to their disease phenotype,
considering disease location, the age at diagnosis, and disease
behaviour by using the Montreal classification. [27,28] The
majority of patients had an onset of the disease in their mid20s
(mean age at first diagnosis of CD: 28.1611.4 years). The mean
age at first diagnosis of UC was 31.8613.7 years. 13.9% of the CD
patients and 12.7% of the UC patients had a positive family
history of IBD.
The results of the CNR1 p.Thr453Thr genotyping analysis in
216 CD patients, 166 UC patients, and 197 controls are shown in
Table 2. The frequencies of heterozygous and homozygous
carriers of this polymorphism did not differ significantly from
the expected ratio according to the Hardy-Weinberg law. Patients
with UC were less likely to be 1359 A/A homozygous (p=0.01,
OR 0.30, 95% CI 0.12–0.78). In contrast, this polymorphism did
not influence susceptibility to CD (Table 2).
The CNR1 1359 G/A (p.Thr453Thr) Polymorphism
Modulates Disease Onset and Body Mass Index in CD
In Table 3, we provide a detailed genotype-phenotype analysis
of the CNR1 1359 G/A polymorphism in CD patients. Carriers of
the 1359 A/A genotype were likely to have a lower body weight
(p=0.0005). In addition, homozygous carriers of the major G
allele were more likely to develop CD before 40 years of age
(p=5.9610
27) than carriers of the minor A allele. There was no
association between the CNR1 p.Thr453Thr polymorphism and
disease location, use of immunosuppressive drugs, family history of
IBD, CD-related surgery, stenoses, and abscesses (Table 3). In
addition, the CNR1 p.Thr453Thr polymorphism did not
influence the UC phenotype (Table 4).
Discussion
We analyzed the effect of the CNR1 p.Thr453Thr polymor-
phism on IBD susceptibility and disease phenotype. This study was
based on our previous results which suggested that CB1 receptor
signaling is involved in defense mechanisms in response to acute
intestinal inflammation in animal models. [3,7] Based on this
knowledge, we hypothesized that differential CB1 receptor
expression, e.g., modulated by genetic factors, may contribute to
IBD susceptibility. In the present study, we focused on the 1359
G/A polymorphism within the CNR1 gene encoding the CB1
receptor, given the importance of this nucleotide substitution in
other endocannabinoid-mediated disorders such as alcohol
dependence [25] and schizophrenia [32]. Although the CNR1
1359 G/A (p.Thr453Thr) SNP is a silent mutation, which does not
result in an amino acid exchange, it might be associated with
alterations e.g. in RNA splicing. [33]
Our study demonstrated an association with UC susceptibility
but not with CD susceptibility. The prevalence of 1359 A/A
homozygous carriers was 10.7% in the control population, 6.9% in
CD patients, and only 3.6% in UC patients. The genotype
frequencies found for our control population were within the values
expected from Hardy-Weinberg equilibrium and were similar to a
previous German control cohort. [29] However, given the limited
size of the study population and the low prevalence of 1359 A/A
homozygous carriers among UC patients, this finding has to be
confirmed in larger replication cohorts. Furthermore, given that the
study was primarily designed to detect differences in the frequency
of IBD risk alleles, the control population was selected only
regardingabsenceofIBDandotherchronicdiseasesaswellasbeing
negative for a family history of IBD. Therefore a selection bias
resulting in differences e.g. in BMI can not be excluded though it is
intriguing that a lower BMI was found with CD and not with UC.
The human CNR1 gene is localized on chromosome 6q14–q15.
[34] Interestingly, an earlier genome-wide family-based linkage
study found an association of this region with celiac disease [35].
We recently demonstrated that celiac disease and UC (but not CD)
share another common susceptibility locus on chromosome 4q27.
[36] Although none of the recent genome-wide association studies
demonstrated the CNR1 gene as a major IBD susceptibility gene, a
previous genome scan in 260 IBD-affected relative pairs found
Table 2. Genotype frequencies of CNR1 1359 G/A
(p.Thr453Thr) polymorphism in patients with Crohn’s disease
(CD) and ulcerative colitis (UC) as well as in controls.
(1)
GG
(2)
GA
(3)
AA (1) vs. (2) (1) vs. (3)
CD 115 (53.3%) 86 (39.8%) 15 (6.9%) CD vs. Controls
(n=216) p=0.83 p=0.28
Controls
(n=197)
103 (52.3%) 73 (37.0%) 21 (10.7%) UC vs. Controls
p=0.74 p=0.01
OR 0.30
CI 0.12–0.78
UC 97 (58.4%) 63 (38.0%) 6 (3.6%) CD vs. UC
(n=166) p=0.52 p=0.17
doi:10.1371/journal.pone.0009453.t002
CNR1 in IBD
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(lod=2.21 between D6S2436/D6S305). [37]
We recently confirmed a number of CD susceptibility genes
found in genome-wide associations studies such as NOD2, [38,39]
IL23R, [40] and ATG16L1 [41], but we also demonstrated
differences in the genetic susceptibility to CD [42], suggesting
that there are differences in the genetic susceptibility to IBD even
between different Caucasian populations. In addition, other
genetic associations such as those of TLR4 SNPs with CD
susceptibility shown by our group [43] were not among the major
CD susceptibility genes in a recent meta-analysis of genome-wide
scans, although this gene has been confirmed as a CD
susceptibility gene. [44]
Currently, it is unknown if the CNR1 1359 G/A (p.Thr453Thr)
SNP modulates CB1 receptor expression or function. Particularly
changes at amino acid positions 418–439 seem to be associated
with a lack of receptor desensitization [45], and allelic variation in
the CNR1 gene was suggested to be associated with a lower rather
than a higher receptor activity, [46] but detailed studies
investigating receptor activity based on different CNR1 genotypes
Table 3. Association between the CNR1 1359 G/A (p.Thr453Thr) genotype and CD characteristics.
(1) GG
(n=114)
(2) GA
(n=86)
(3) AA
(n=15)
(1) vs (2)
P value
(1) vs (3)
P value
(1) vs (2)+(3)
P value
Male sex 56 (49.1%) 41 (47.7%) 8 (53.3%) p=0.89 p=0.79 p=1.00
Body mass index (kg/m
2)
Mean 6 SD 23.964.0 22.163.5 22.063.6 p=0.001 p=0.05 p=0.0005
Range 16–34 16–32 18–31
Age at diagnosis (yr)
Mean 6 SD 26.9610.6 29.7612.0 27.2614.1 p=0.09 p=0.78 p=0.11
Range 7–57 13–67 16–52
Disease duration (yr)
Mean 6 SD 13.168.4 14.468.9 10.867.6 p=0.31 p=0.31 p=0.52
Range 2–44 3–35 3–26
Age (yr)
Mean 6 SD 39.9611.5 44.0611.7 37.2612.1 p=0.01 p=0.46 p=0.05
Range 17–70 23–71 19–56
Age at diagnosis
,17 years (A1) 0 (0.0%) 0 (0.0%) 0 (0.0%) p=8.6 610
28 p=0.33 p=5.9 610
27
17–40 years (A2) 89 (78.1%) 35 (40.7%) 10 (66.7%)
.40 years (A3) 25 (21.9%) 51 (59.3%) 5 (33.3%)
Location
Terminal ileum (L1) 12 (10.5%) 8 (9.3%) 2 (13.3%) p=1.00 p=0.67 p=1.00
Colon (L2) 19 (16.7%) 18 (20.9%) 4 (26.7%) p=0.47 p=0.47 p=0.39
Ileocolon (L3) 60 (52.6%) 43 (50.0%) 7 (46.7%) p=0.78 p=0.79 p=0.68
Upper GI (L4) 23 (20.2%) 17 (19.8%) 2 (13.3%) p=1.00 p=0.73 p=0.86
Ileal involvement (L1 + L3) 72 (63.2%) 51 (59.3%) 9 (60.0%) p=0.66 p=0.78 p=0.18
Behaviour
Non-sticturing, Non penetrating (B1) 22 (19.3%) 17 (19.8%) 4 (26.7%) p=1.00 p=0.50 p=0.86
Stricturing (B2) 33 (28.9%) 18 (20.9%) 3 (20.0%) p=0.25 p=0.56 p=0.21
Penetrating (B3) 59 (51.8%) 51 (59.3%) 8 (53.7%) p=0.32 p=1.00 p=0.34
Use of immunosuppressive agents 90 (78.9%) 64 (74.4%) 11 (73.3%) p=0.50 p=0.74 p=0.42
Extraintestinal manifestations 80 (70.2%) 55 (64.0%) 11 (73.3%) p=0.36 p=1.00 p=0.47
Positive family history of IBD 29 (25.4%) 13 (15.1%) 3 (20.0%) p=0.08 p=0.76 p=0.09
Surgery because of CD 65 (57.0%) 54 (62.8%) 8 (53.3%) p=0.47 p=0.79 p=0.58
Fistulas 59 (51.8%) 51 (59.3%) 8 (53.3%) p=0.32 p=1.00 p=0.34
Stenosis 78 (68.4%) 58 (67.4%) 9 (60.0%) p=0.88 p=0.56 p=0.77
Abscesses 41 (36.0%) 32 (37.2%) 4 (26.7%) p=0.88 p=0.57 p=1.00
1Disease behavior was defined according to the Montreal classification [28]. A stricturing disease phenotype was defined as presence of stenosis without penetrating
disease. The diagnosis of stenosis was made surgically, endoscopically, or radiologically (using MRI enteroclysis).
2Immunosuppressive agents included azathioprine, 6-mercaptopurine, 6-thioguanin, methotrexate, and/or infliximab.
3Extraintestinal manifestations were defined as one or more of the following IBD-related diseases: non-medication-induced arthropathies (e.g., ankylosing spondylitis,
sacroileitis, peripheral arthritis), eye involvement (e.g., episcleritis and/or iritis/uveitis), skin involvement (e.g., erythema nodosum and pyoderma gangrenosum), non-
medication-induced biliary disease (e.g., sclerosing cholangitis).
4Only surgery related to CD-specific problems (e.g., fistulectomy, colectomy, ileostomy) was included.
doi:10.1371/journal.pone.0009453.t003
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reduced CB1 activity would also explain the low BMI found in the
1359 A/A homozygous CD patients. Consistent with these data,
the 1359 G/G wildtype genotype has been shown to be associated
with an increased BMI and overweight in an Italian study of a
healthy population. [47] A low BMI in CD patients is also
considered to be an indicator of high disease activity. Therefore,
1359 A/A homozygosity could contribute to a more severe disease
phenotype. This would be consistent with our results in CNR1
2/2
mice, demonstrating that these knockout mice take a more
fulminate course in DNBS and DSS colitis. [3] However,
functional experiments have to analyze if CNR1 signaling is
indeed decreased in 1359 A/A homozygous patients.
Our findings add evidence that targeting the CB1 receptor
system may modulate intestinal inflammation, suggesting this
receptor as a potential target for future treatments. Similarly,
animal models suggest that CB1 receptor activation with
exogenous CB1 receptor agonists induces protection against
intestinal inflammation. [3,5] Therefore, the increased CB1
receptor expression seen in murine colitis models is likely an
intrinsic protective mechanism to counter-regulate the deleterious
effects of intestinal inflammation. The physiological importance of
the CB1 receptor and the endocannabinoid system becomes
obvious when endocannabinoid levels are increased by blocking
their degradation. Under these circumstances, intestinal inflam-
mation is reduced and the CB1 receptor is involved in this
protection, emphasizing the important pathophysiological role of
this system in intestinal inflammation. [7] Whether monitoring of
CB1 receptor function or genotyping can identify responders of
future treatments targeting the CB1 receptor remains speculative
and has to be clarified in clinical trials.
In summary, we demonstrate that the CNR1 1359 G/A
polymorphism modulates IBD susceptibility and phenotype.
Specifically, we show that 1359 A/A homozygosity protects
against UC and that CD patients carrying the minor A allele have
a later disease onset and a lower BMI. These findings have to be
confirmed in a larger replication study. Given the low prevalence
of 1359 A/A homozygous carriers, this likely can be achieved only
in a large multicenter trial. Nevertheless, our findings provide
further evidence that endocannabinoids modulate intestinal
inflammation, suggesting that this system could act as a target
for future therapeutic interventions.
Table 4. Association between CNR1 1359 G/A (p.Thr453Thr) genotype and UC disease characteristics.
(1)
GG
(n=97)
(2)
GA
(n=63)
(3)
AA
(n=6)
(1) vs. (2)
p value
(1) vs. (3)
p value
(2) vs. (3)
p value
(1) vs. (2)+(3)
p value
Male sex 47 (48.5%) 32 (50.8%) 4 (66.7%) p=0.87 p=0.44 p=0.68 p=0.75
Body mass index (kg/m
2)
Mean 6 SD 23.863.7 24.464.9 26.564.6 p=0.46 p=0.27 p=0.39 p=0.30
Range 16–32 18–41 20–32
Age at diagnosis (yr)
Mean 6 SD 31.7613.9 31.7613.4 34.5617.0 p=0.99 p=0.70 p=0.70 p=0.92
Range 9–73 14–81 13–57
Disease duration (yr)
Mean 6 SD 11.966.5 12.368.7 14.2611.1 p=0.79 p=0.64 p=0.70 p=0.68
Range 2–2 9 2–41 4–36
Age (yr)
Mean 6 SD 43.7614.2 43.9615.1 48.7611.9 p=0.93 p=0.37 p=0.40 p=0.79
Range 21–81 20–86 37–68
Location
Rectum 21 (21.7%) 7 (11.1%) 1 (16.7%) p=0.13 p=1.00 p=0.55 p=0.10
Left-sided 28 (28.9%) 28 (44.4%) 2 (33.3%) p=0.06 p=1.00 p=0.69 p=0.07
Pancolitis 48 (49.4%) 28 (44.4%) 3 (50.0%) p=0.63 p=1.00 p=1.00 p=0.64
Use of immunosuppressive agents 67 (69.1%) 48 (76.2%) 4 (66.7%) p=0.37 p=1.00 p=0.63 p=0.39
Use of infliximab 27 (27.8%) 11 (17.5%) 1 (16.7%) p=0.18 p=1.00 p=1.00 p=0.14
Surgery due to UC 4 (4.1%) 0 (0.0%) 0 (0.0%) p=0.15 p=1.00 p=1.00 p=0.14
Fistulas 4 (4.1%) 3 (4.8%) 0 (0.0%) p=1.00 p=1.00 p=1.00 p=1.00
Stenosis 15 (15.5%) 4 (6.3%) 1 (16.7%) p=0.13 p=1.00 p=0.37 p=0.15
Abscesses 5 (5.2%) 4 (6.3%) 0 (0.0%) p=0.74 p=1.00 p=1.00 p=1.00
Extraintestinal manifestations 14 (14.4%) 11 (17.5%) 0 (0.0%) p=0.66 p=1.00 p=0.58 p=0.83
Positive family history 15 (15.5%) 6 (9.5%) 0 (0.0%) p=0.34 p=0.59 p=1.00 p=0.24
1Immunosuppressive agents included azathioprine, 6-mercaptopurine, and/or infliximab.
2Only UC-related surgery (e.g., colectomy) was included.
3Extraintestinal manifestations were defined as one or more of the following IBD-related diseases: non-medication-induced arthropathies (e.g., ankylosing spondylitis,
sacroileitis, peripheral arthritis), eye involvement (e.g., episcleritis and iritis/uveitis), skin involvement (e.g., erythema nodosum and pyoderma gangrenosum), non-
medication-induced biliary disease (e.g., sclerosing cholangitis).
doi:10.1371/journal.pone.0009453.t004
CNR1 in IBD
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